
US clinical-stage biotech PDS Biotechnology (Nasdaq: PDSB) saw its shares rocket 183% to $0.62 today, after it announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (PIPE) transaction.
The round was led by Nant Capital, with additional participation by current investors. In connection with the PIPE, Nant will have the right to designate two members to join the company’s board of directors, one of whom will be Dr Patrick Soon-Shiong, for so long as it beneficially owns 15% or more of the company’s outstanding common stock. The PIPE consists of an initial closing (the Initial Closing) and a contingent milestone closing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze